Stanford Peng is a member of Gentibio scientific advisory board. He is President and Head of Research and Development at Alpine Immune Sciences (NASDAQ: ALPN) and a practicing rheumatologist. Before joining Alpine Immune Sciences, Stanford was Chief Medical Officer at Stemcentrx, Inc., until its acquisition by AbbVie and previously held various positions at Seattle Genetics and Roche, as well as the Benaroya Research Institute and Washington University in St. Louis. Dr. Peng received a B.A. and B.S. in Music and Biological Sciences from Stanford University, as well as an M.D. and Ph.D. in Biology from Yale University. He conducted his residency in internal medicine at the University of Pennsylvania and was a Clinical and Research Fellow in rheumatology at Brigham & Women’s Hospital.
Stanford Peng, MD, PhD
President, R&D, Alpine Immune Sciences